• SUNITHA SUKUMARAN Department of Pharmaceutical Chemistry and Analysis, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Institute of Medical Science, Amrita Health Science Campus Kochi 682041, Kerala, India
  • S. SATHIANARAYANAN Department of Pharmaceutical Chemistry and Analysis, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Institute of Medical Science, Amrita Health Science Campus Kochi 682041, Kerala, India




Corona Virus, Treatment, Vaccines, Mutant strain virus


Covid19 (Coronavirus) is a life-threatening virus that mainly affects our respiratory system, kidney, and GIT tract. People with a low immune system in their body fall prey to it. This virus (2019-nCoV) spreads easily from one person to another. As there is no treatment to kill the virus, the only way to stop this pandemic is through precautions and reduce the viral load in the body. This review reveals the main types of coronaviruses, history, pathophysiology, current treatment, drawbacks of current treatment, targets for drug development against Covid-19, vaccines discovered for covid-19, side effects of the currently available vaccines, and current status of this situation. The main mechanism of action of the virus easily enters to bind with the Angiotensin-Converting Enzyme 2 (ACE2) in the human body cells. Management of the virus several approaches will be taken mainly isolation of the patients and contacts the contacts, oxygen therapy for respiratory failure patients based on the severity Remdesivir, Lopinavir/ritonavir, Chloroquine, and Hydroxychloroquine, Alpha-interferon and plasma therapy can be used to control the infections. In India, AYUSH is also recommended to enhance the immune system through herbal-based products, Vaccination is also recommended by most of the countries, but many side effects and drug-drug interactions were reported for the above treatments. So that in future a new way of approach should be developed by our health organization as soon as possible.


Download data is not yet available.


Thiel V. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol 2003;84:2305-15.

Menon JC, Rakesh PS, John D, Thachathodiyl D, Banerjee A. What was right about Kerala's response to the COVID-19 pandemic. BMJ Global Health 2020;5:e003212.

Weiss SR, Navas MS. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005;69:635–64.

Vijaykrishna D, Smith GJ, Zhang JX, Peiris JS, Chen H, Guan Y. Evolutionary insights into the ecology of coronaviruses. J Virol 2007;81:4012-20.

Gouilh MA, Puechmaille SJ, Gonzalez JP, Teeling E, Kittayapong P, Manuguerra JC. SARS-coronavirus ancestor's footprints in South-East Asian bat colonies and the refuge theory. Infect Genet Evol 2011;11:1690-702.

Lawrence CM, Menon S, Eilers BJ, Bothner B, Khayat R, Douglas T, et al. Structural and functional studies of archaeal viruses. J Biol Chem 2009;284:12599-603.

Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J 2005;24:S223-7, S226.

Dos Santos WG. Natural history of COVID-19 and current knowledge on therapeutic treatment options. Biomed Pharmacother 2020;129:110493.

Sreeja N, Muthukumar M, Latha SM. Assessment on the impact of Covid-19 pandemic on fear and socioeconomic status among south Indian population. Int J Pharm Pharm Sci 2020;12:52-6.

Lai MM, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res 1997;48:1-100.

Vijgen L, Keyaerts E, Moes E, Thoelen I, Wollants E, Lemey P, et al. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol 2005;79:1595-604.

Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J 2020;55:2000607.

Niharika D, B Niharika, T Aishwarya, A Nikitha, R Butool, M Ibrahim, et al. Coronavirus-a virus in learning. Int J Curr Pharm Res 2020;12:7-10.

Fung To S, Liu Ding X. Coronavirus infection, ER stress, apoptosis, and innate immunity. Front Microbiol 2014;5:296.

Edwards RA, Rohwer F. Viral metagenomics. Nat Rev Microbiol 2005;1:504-10.

De CE. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther 2006;4:291-302.

Lau AC, So LK, Miu FP, Yung RW, Poon E, Cheung TM, et al. Outcome of coronavirus-associated severe acute respiratory syndrome using a standard treatment protocol. Respirology 2004;9:173-83.

Elston DM. COVID, Biologics, and psoriasis therapy. J Am Acad Dermatol 2020;83:1577-8.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of covid-19-final report. N Engl J Med 2020;383:1813-26.

Joicy J, Johnson VB, Bharat M. Convalescent plasma therapy: a novel approach to a novel coronavirus. Int J Pharm Pharm Sci 2020;12:180-2.

Xuelin S, Shaoqiang Li, Kexin Li, Xin Hu. Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID-19), Aging Medicine 2020;3:98-101.

Paula MS, Nathane SF, Pedro LS, Chiara R, Denise B, Paolo P. Pros and cons of corticosteroid therapy for COVID-19 patients. Respir Physiol Neurobiol 2020;280:103492.

Ambrish S. Drug targets for COVID-19 therapeutics: ongoing global efforts. J Biosci 2020;45:87.

Reza KK, Mohammad KK, Alireza N. COVID-19 target: a specific target for novel coronavirus detection. Gene Reports 2020;20:100740.

Carmen G, Tiziana G, Vanesa N, Jesus U. COVID-19: drug targets and potential treatments. J Med Chem 2020;63:12359–86.

Yahira MB Santos, Sarah EJ, Andrew DM. The SARS-coronavirus papain-like protease: structure, function, and inhibition by designed antiviral compounds. Antiviral Res 2015;115:21-38.

Lin MH, Moses DC, Hsieh CH, Cheng SC, Chen YH, Sun CY, et al. Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res 2018;150:155-63.

Thanigaimalai P, Manoj M, Vigneshwaran N, Yoshio H, Sang HJ. An overview of severe acute respiratory syndrome–coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem 2016;59:6595–628.

Douangamath A, Fearon D, Gehrtz P, Krojer T, Lukacik P, Owen CD, et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun 2020;11:5047.

Lee CC, Kuo CJ, Hsu MF, Liang PH, Fang JM, Shie JJ, Wang AH. Structural basis of mercury-and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors. FEBS Lett 2007;581:5454-8.

Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for the design of improved α-ketoamide inhibitors. Science 2020;368:409-12.

Aftab SO, Ghouri MZ, Masood MU. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J Transl Med 2020;18:275.

Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020;368:1499-504.

Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 2019;10:2342.

Francis JB, Hind SA, Waad MAO, Abdallah MI, Noor B, Mohammed S, et al. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2. Arch Med Sci 2020;16:508–18.

Viswanathan T, Arya S, Chan SH. Structural basis of RNA cap modification by SARS-CoV-2. Nat Commun 2020;11:3718.

Suranga LS. Overcoming nonstructural protein 15-nidoviral uridylate-specific endoribonuclease (nsp15/NendoU) activity of SARS-CoV-2. Future Drug Discovery 2020;2:FDD42.

Rosas Lemus M, Minasov G, Shuvalova L, Inniss NL, Kiryukhina O, Brunzelle J, et al. High-resolution structures of the SARS-CoV-2 2'-O-methyltransferase reveal strategies for structure-based inhibitor design. Sci Signal 2020;13:eabe1202.

Hänel K, Stangler T, Stoldt M, Willbold D. Solution structure of the X4 protein coded by the SARS-related coronavirus reveals an immunoglobulin-like fold and suggests a binding activity to integrin I domains. J Biomed Sci 2006;13:281-93.

Wu K, Peng G, Wilken M, Geraghty RJ, Li F. Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus. J Biol Chem 2012;287:8904-11.

Surya W, Li Y, Torres J. Structural model of the SARS coronavirus E channel in LMPG micelles. Biochim Biophys Acta Biomembr 2018;1860:1309-17.

Huang Q, Yu L, Petros AM, Gunasekera A, Liu Z, Xu N, et al. Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein. Biochemistry 2004;43:6059-63.

Towler P, Staker B, Prasad SG, Menon S, Tang J. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem 2004;279:17996-8007.

Linda BB, Neeraj S, Eran E, Aleksandar S, Alan H, Rafael F. Targeting TMPRSS2 in SARS-CoV-2 infection. Mayo Clin Proc 2020;95:1989-99.

Giuseppe M. SARS-CoV-2 and COVID-19: what are our options? Where should we focus our attention on to find new drugs and strategies. Travel Med Infect Dis 2020;37:101685.

Dahms SO, Arciniega M, Steinmetzer T, Huber R, Than ME. Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism. Proc Natl Acad Sci USA 2016;113:11196-201.

Li J, Zhu R, Chen K, Zheng H, Zhao H, Yuan C, et al. Potent and specific Atg8-targeting autophagy inhibitory peptides from giant ankyrins. Nat Chem Biol 2018;14:778-87.

Adithya J, Bhagyalakshmi N, Aishwarya S, Lekshmi RN. The plausible role of Indian traditional medicine in combating corona virus (SARS-CoV 2): a mini-review. Curr Pharm Biotechnol 2021;22:906-19.

Papia C. In silico investigation of phytoconstituents from Indian medicinal herb, ‘Tinospora cordifolia (giloy)’ against SARS-CoV-2 (COVID-19) by molecular dynamics approach. J Biomol Struct Dyn 2020:1-18. DOI:10.1080/07391102.2020.1803968

Mansi P, N Latha. In silico studies reveal potential antiviral activity of phytochemicals from medicinal plants for the treatment of COVID-19 infection. 2020. DOI:10.21203/rs.3.rs-22687/v1

Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm NM, et al. Vaccines for COVID-19. Clin Exp Immunol 2020;202:162-92.

Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res 2020;288:198114.

Daniel ES, Martin FB. COVID-19: mechanisms of vaccination and immunity. Vaccines 2020;8:404.

Zhang Y, Gang Z, Hongxing P. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 y: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. medRxiv 2020. https://doi.org/10.1101/2020.07.31.20161216

Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci 2021;25:1663-9.

Østergaard SD, Schmidt M, Horvath Puho E, Thomsen RW, Sørensen HT. Thromboembolism and the oxford-astrazeneca COVID-19 vaccine: side-effect or coincidence. Lancet 2021;397:1441-3.

AG Al Sehemi, Olotu FA, Dev S, Pannipara M, Soliman, Bijo M. Natural products database screening for the discovery of naturally occurring SARS-Cov-2 spike glycoprotein blockers. Chem Select 2020;5:13309-17.

Bilha B, Aswathy RD, Bhagyalakshmi N, Lekshmi RN. The impetus of COVID-19 in multiple organ affliction apart from respiratory infection: pathogenesis, diagnostic measure s and current treatment strategy. Infect Disord Drug Targets 2020;20:1-13.

Matta S, Rajpal S, Chopra KK, Arora VK. Covid-19 vaccines and new mutant strains impacting the pandemic. Indian J Tuberc 2021;68:171-3.

Conti P, Caraffa A, Gallenga CE, Kritas SK, Frydas I, et al. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. J Biol Regul Homeost Agents 2021;35:1-4.

Shanker M, Sanjay R, KK Chopra, VK Arora. Covid-19 vaccines and new mutant strains impacting the pandemic. Indian J Tuberc 2021;68:171-3.



How to Cite

SUKUMARAN, S., & SATHIANARAYANAN, S. (2021). A REVIEW ON COVID-19 PANDEMIC A GLOBAL THREAT-CURRENT STATUS AND CHALLENGES AND PREVENTIVE STRATEGIES. International Journal of Applied Pharmaceutics, 13(5), 10–14. https://doi.org/10.22159/ijap.2021v13i5.42070



Review Article(s)